Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other

Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies

Daiichi Sankyo Partnership Validates MNM Platform but Financial Terms Remain Opaque

By The Northwire Desk — AI Analysis Apr 16, 2026 · 05:48 4568
Executive Summary
  • Interna Therapeutics announced a research collaboration with Daiichi Sankyo (via its Boston Research Institute) on April 16, 2026.
  • The partnership focuses on evaluating Interna's Molecular Nano Motor (MNM) technology as a delivery enhancer for targeted therapeutics.
  • Scope includes preclinical evaluation to improve intracellular delivery and tissue penetration without traditional delivery systems.
  • Financial terms of the collaboration were not disclosed.
  • The agreement allows for potential expansion into broader research based on successful outcomes.
  • Contextual Note: A separate news release from April 1, 2026, details Nuvation Bio acquiring Japan rights to Safusidenib from Daiichi Sankyo. These are distinct entities; investors must not conflate the two partnerships or assets.
Material Impact
  • Validation vs. Cash: The collaboration validates Interna's MNM platform with a top-tier global pharmaceutical partner (Daiichi Sankyo). However, without disclosed upfront payments or milestone structures, immediate financial materiality is low.
  • Stage of Development: The work is preclinical. Success in this phase does not guarantee clinical efficacy or regulatory approval, maintaining high technical risk.
  • Comparison to Historical Context: Unlike the Nuvation Bio deal (April 1), which involved acquiring rights to a Phase 3 asset with existing data, Interna's deal is for platform technology research. This represents an earlier stage of de-risking compared to licensing a near-commercial drug.
  • Risk-Averse View: While positive for credibility, the lack of financial terms suggests this may be a low-cost research agreement rather than a transformative investment. It does not immediately solve capital needs or guarantee revenue streams in the next 12 months.
4568 · Price
Company Overview
  • Company: Interna Therapeutics is a biotechnology company focused on drug delivery technologies.
  • Flagship Technology: Molecular Nano Motor (MNM) platform designed to enable efficient intracellular delivery and improved tissue penetration.
  • Development Stage: Preclinical evaluation phase in collaboration with Daiichi Sankyo.
  • Differentiation: Claims to operate without reliance on traditional delivery systems, potentially reducing toxicity or improving efficacy of nucleic acids and macromolecules.
Read the original news release →

More from

May 28, 2026 · 14:50

Daiichi Sankyo’s Vanflyta secures Canadian public reimbursement, a measured step in global AML market access.

Other Apr 01, 2026 · 08:00

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

M&A / Property